Article

Associations between Serum Saturated Fatty Acids Content and Mortality in Dialysis Patients

Malgorzata Sikorska-Wisniewska 1, Adriana Mika 2,3*, Tomasz Sledzinski 2 and Michal Chmielewski 1,*

1 Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland
2 Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Medical University of Gdansk, 80-210 Gdansk, Poland
3 Department of Environmental Analysis, Faculty of Chemistry, University of Gdansk, 80-309 Gdansk, Poland
* Correspondence: chmiel@gumed.edu.pl

Abstract: Background: Cardiovascular mortality in dialysis population remains very high. Saturated fatty acids (SFA) contribute to atherosclerosis and to cardiovascular risk. Aim: The aim of this study was to evaluate the relationship between mortality in dialysis patients and the serum SFA content. Methods: Survival of 54 patients on dialysis was assessed. A total of 21 SFA from patients' sera were measured by gas chromatography-mass spectrometry (GC-MS). Diet was assessed by food frequency questionnaire FFQ-6. The SFA content is presented as fatty acid proportion (%). Results: During the observation time (median 66 months) 22 patients died. There was a significant relationship between elevated SFA (above SFA mean) and mortality (log-rank 3.13; \( p = 0.0017 \)). Moreover, patients who ingested foods rich in SFA, according to FFQ-6, had a higher mortality risk (log-rank 2.24; \( p = 0.03 \)). The hazard ratio for mortality associated with increased SFA content equalled 4.47 (1.63–12.26). Addition of age and inflammation (hsCRP > 5 mg/L) into the Cox model did not modify this relationship. However, SFA content turned out to be significantly higher in patients with diabetes mellitus and cardiovascular disease, as compared to patients free from these co-morbidities. Their addition to the model attenuated the relationship between SFA and mortality, making it statistically insignificant. Conclusion: The serum content of SFA turned out to be a strong predictor of mortality in dialysis patients. However, given the significant associations between SFA, DM, and CVD, interventional studies with controlled SFA intake are needed to evaluate the causal links between SFA, co-morbidities and survival.

Keywords: saturated fatty acids; lipids; dialysis; chronic kidney disease

1. Introduction

The prevalence of chronic kidney disease (CKD) is estimated at a rate as high as 6–13% of the general population [1,2]. Moreover, it is still increasing, owing to the increased proportion of elderly individuals and patients diagnosed with diseases that contribute to CKD such as obesity, hypertension, diabetes mellitus (DM), and cardiovascular disease (CVD). Mortality rates of CKD patients are higher than in people free from kidney diseases, and they increase with the disease progression [3]. In patients with end-stage renal disease (ESRD) treated with dialysis, mortality risk is several times higher than in the general population with CVD being the major cause of premature death.

In the general population, lipid disorders are among the most acknowledged risk factors for CVD. In dialysis patients, atherosclerotic dyslipidaemia is prevalent. Hypertriglyceridaemia and low-HDL cholesterol concentration are the most typical and potentially deleterious lipid abnormalities in the course of CKD [4]. However, our previous studies, among others, have also shown profound alterations in other lipid classes including significant disturbances in the serum profile of fatty acid content [5].
Fatty acids, carboxylic acids with an aliphatic chain, either saturated or unsaturated, play numerous crucial functions in the organism mainly as energy sources and membrane constituents. Saturated fatty acids (SFA) have only single bonds in their chains. They are mainly obtained through dietary intake of animal fats. In the general population, SFA have been linked to increased cardiovascular risk. Leading to an increase in low density lipoprotein (LDL) cholesterol concentration, they are thought to promote atherosclerosis, and hence, cardiovascular disease and mortality risk [6,7]. However, current studies in this area demonstrate discrepant results, generating contrary guidelines and opinions from firm recommendations to control SFA intake to a total neglection of their role in CVD progression [8,9]. Data in the CKD population are scarce, although there are studies demonstrating direct associations between the total serum SFA level and the risk of sudden cardiac death, perhaps in a mechanism that includes mitochondrial and cell damage triggered by SFA accumulation [10,11].

The aim of this study was to evaluate the relationship between mortality in dialysis patients and the serum content of saturated fatty acids (SFA).

2. Materials and Methods

The study was performed based on a group of 54 ESRD patients, treated with dialysis in a single university-based dialysis centre. Exclusion criteria were as follows: intake of fatty acids supplements, acute inflammatory state, and unwillingness to participate in the study. Half of the group (n = 27) was undergoing hemodialysis (HD) treatment, while the other half was on peritoneal dialysis (PD). Presence of diabetes mellitus (DM) and CVD was determined on the basis of patients’ medical charts.

Blood was collected prior to an HD session in HD patients and during a routine check-up visit in PD subjects. Serum was stored at −80 °C, until analysed. A total of 21 SFA from patients’ sera were measured by gas chromatography-mass spectrometry (GC-MS). Total lipids were extracted from whole serum samples in a chloroform–methanol mixture (2:1, v/v) following the method by Folch et al. [12], as described previously [5]. The SFA content is presented as fatty acid proportion (%). Circulating levels of high-sensitivity C-reactive protein (CRP), albumin, total and HDL cholesterol as well as triglycerides were analysed using certified methods at the central university laboratory.

Diet was assessed by food frequency questionnaire (FFQ-6), the most common dietary assessment tool used in large epidemiologic studies of diet and health and validated for the national population [13].

Protocol of the study received approval from the Local Bioethics Committee at the Medical University of Gdansk (protocol no. NKEBN/614/2013-2014) and informed consents were obtained from all the patients.

Results are expressed as mean and standard deviation or median and interquartile range, as appropriate. The assumption of normality was verified with the Kolmogorov–Smirnov test. A p value < 0.05 was considered to be statistically significant. Comparisons between two groups were assessed with a Student’s t-test, or a Mann–Whitney test, as appropriate. To assess correlations among the evaluated variables, Pearson’s correlation coefficient (r) was used. Survival analyses were made with the Kaplan–Meier survival curve and the Cox proportional hazard model, presenting data as hazard ratio (HR; 95% confidence intervals (CI)). Statistical processing of the results was performed with the use of the statistical software Statistica PL version 13.0 (StatSoft, Krakow, Poland).

3. Results

Out of the 54 patients under study, 12 had been diagnosed with DM, and 26 with CVD. The median of the observation time was 66 months (range 2–76 months). During the observation, 22 patients died. Kaplan–Meier analysis revealed a significant relationship between elevated SFA (above SFA mean) and mortality (log-rank 3.13; p = 0.0017) (Figure 1). In the Cox regression model, the hazard ratio for mortality associated with increased SFA content equalled 4.47 (1.63–12.26). Moreover, patients who ingested foods rich in SFA,
according to FFQ-6, had a higher mortality risk (log-rank 2.24; \( p = 0.03 \)) (Figure 2). However, as seen in Table 1, containing the general characteristics of the studied patients divided into groups according to SFA mean, patients with high SFA content turned out to be slightly older, more inflamed, and had a higher prevalence of DM and CVD (Table 1). Indeed, SFA content was significantly higher in diabetic patients, as compared to patients free from DM (35.2 ± 1.6 vs. 33.3 ± 2.8; \( p = 0.03 \)), and was elevated in patients with CVD when compared to patients without it (34.9 ± 1.8 vs. 32.6 ± 2.9; \( p < 0.001 \)). In Cox regression, the addition of age and inflammation (hsCRP > 5 mg/L) into the model did not modify the relationship between high SFA and mortality. However, addition of DM and CVD attenuated this relationship, making it statistically insignificant; HR 2.47 (0.78–7.71). According to food questionnaires, SFA content was associated with ingestion of food rich in saturated fat, although these relationships did not reach statistical significance. No associations between SFA and lipoprotein subclasses or with total cholesterol were observed. Sub-group analyses in patients stratified according to the use of HMG-CoA inhibitors revealed comparable results (Table S1). There were also no significant differences in the analysed variables between HD and PD patients (Table S2).

Figure 1. Survival curves of dialysis patients according to their saturated fatty acids (SFA) content.

Figure 2. Survival curves of dialysis patients according to their saturated fatty acids (SFA) intake.
Table 1. Baseline characteristics of the studied dialysis patients stratified according to their saturated fatty acids (SFA) content; CRP—high sensitivity C-reactive protein, DM—diabetes mellitus, CVD—cardio-vascular disease, TC—total cholesterol, HDL—high density lipoprotein cholesterol, LDL—low density lipoprotein cholesterol, TG—triglycerides.

|                     | Low SFA (n = 27) | High SFA (n = 27) | p-Value |
|---------------------|-----------------|-----------------|---------|
| Age (years)         | 53.8 ± 15.7     | 59.9 ± 9.5      | 0.09    |
| CRP (mg/L)          | 2.94 (1.17–7.81)| 6.80 (1.64–9.71)| 0.06    |
| DM (%)              | 10.7            | 32.1            | <0.01   |
| CVD (%)             | 25.0            | 71.4            | <0.01   |
| Albumin (g/L)       | 32.4 ± 4.0      | 31.6 ± 4.2      | 0.45    |
| TC (mg/dL)          | 203.0 (167.0–247.0) | 169.0 (151.0–203.5) | 0.12    |
| HDL (mg/dL)         | 38.5 (34.0–47.0) | 37.0 (32.0–43.5) | 0.43    |
| LDL (mg/dL)         | 115.0 (99.0–117.0) | 92.5 (72.0–125.0) | 0.05    |
| TG (mg/dL)          | 192.0 (108.5–197.0) | 178.5 (121.5–233.0) | 0.36    |

4. Discussion

In the present study, the serum content of SFA in dialysis patients turned out to be a strong predictor of mortality. However, since it was heavily dependent on the presence of DM and CVD, including these co-morbidities into the analysis attenuated the associations between SFA and outcome to a statistically insignificant level. Moreover, patients who ingested foods rich in SFA, according to FFQ-6, had a higher mortality risk in our analysis. Similarly, this association lost its significance after accounting for the above confounders.

In the general population, SFA intake and their content is generally believed to promote atherosclerosis, and in consequence, the cardiovascular risk [8]. The major mechanism probably includes the impact of SFA intake and content on increasing the total and LDL cholesterol level [14]. However, no clear associations have been observed between high content/intake of SFAs and the risk of atherosclerotic progression, and most of our understanding of their potential detrimental role is derived from observational studies, which are subject to numerous confounders as demonstrated in our study.

Cardiovascular disease is responsible for the largest proportion of deaths worldwide, and fatty acid profile is a potentially modifiable risk factor for the development of CVD, e.g., through dietary modifications; hence studies evaluating this issue seem of utmost clinical importance. Most public health dietary guidelines recommend limiting SFA intake [15–17]. These recommendations are based on numerous studies, mainly observational, demonstrating cardiovascular benefits associated with reducing SFA intake and/or replacing it with dietary polyunsaturated fatty acids (PUFA). For instance, a meta-analysis of eight clinical studies on replacing SFA with PUFA (combined n = 13,614 participants) estimated a CVD risk reduction of about 10% for each 5% energy replacement; an effect comparable to that predicted from the effects of the intervention on TC:HDL cholesterol ratio [18]. This may be especially important in dialysis patients, since our previous study showed decreased PUFA content in this group [19].

However, there are also opinions neglecting the role of SFA in CVD risk. A meta-analysis summarizing data related to SFA and CVD from 21 prospective epidemiologic studies (combined n = 347,747 participants) did not demonstrate significant associations between the intake of SFA and the risk of chronic heart disease and/or stroke [20]. These findings were consistent with yet another systematic review that showed a nonsignificant association of SFA with CVD [21]. It might be that SFA are most commonly replaced with carbohydrates, hence the lack of association between SFA and the risk of CVD can be interpreted as the lack of benefit of substitution of carbohydrates for saturated fat. Indeed, a pooled analysis of 11 cohort studies (combined n = 344,696 persons) demonstrated that replacement of SFA with polyunsaturated fat, but not carbohydrate or monounsaturated fat, was associated with decreased CVD risk [22].
Regardless of the mechanisms, the discrepant results of the above studies and meta-analyses result in contrary guidelines and opinions, either recommending reduction in SFA intake or neglecting such an approach [8,9].

In dialysis patients, the data on SFA with regard to CVD risk are scarce. Individual studies demonstrate some relations between serum SFA content and mortality in this patient population. In an analysis by Friedman et al. [11], a 0.1% increase in total serum SFA levels was associated with a 1% increase in the odds of sudden cardiac death of HD patients. The authors linked their observations to pro-arrhythmic potential of SFA, observed in some experimental studies [23,24]. The significant association between mortality and SFA intake, found in our study, supports (to some extent) the importance of SFA intake in the dialysis patient population.

Our results show that observational studies are laden with the influence of confounders. The content of SFA turned out to be significantly higher in diabetic patients, as compared to subjects free from DM. This obviously influenced the associations between SFA and outcome, as DM patients are characterized by substantially increased mortality risk, observed also in our analysis. It is difficult to speculate on the potential mechanisms of increased SFA in diabetic patients. It might be that their diet, with limited carbohydrate intake, is automatically more abundant in lipids, including SFA. However, there are studies actually linking circulating SFA to the incidence of type 2 DM [25–27]. Diet rich in SFA is typically associated with increased risk of weight gain, a risk factor for type 2 DM development. Moreover, SFA and their derivatives, ceramides, have been shown to induce insulin resistance [28,29].

Similarly, in our analysis, serum SFA content was increased in patients who had been diagnosed with CVD. This severe co-morbidity is constantly associated with impaired survival. This association was also evident in our study, as CVD patients presented with a significantly worse mortality risk in survival analysis, in comparison to dialysis subjects without this co-morbidity. In the general population, the links between dyslipidemia and CVD are even more acknowledged than in the case of DM. SFA, through their impact on the concentration of LDL cholesterol and on the structure of LDL particles, promote atherosclerosis, and hence CVD [6].

Obviously, to determine whether the links among SFA, DM, CVD and patient outcome are causative and to track potential mechanisms responsible for the above associations, prospective interventional studies are needed. In the general population, such studies are limited by a reliance on nutritional assessment methods of varying reliability, and the assumption that diets remain constant over the study period. In dialysis patients, additional difficulties include other, disease-associated dietary restrictions, and the risk of malnutrition, or protein-energy wasting. Indeed, additional mechanisms and/or non-causative relationships between SFA and mortality include their associations with sarcopenia. This deleterious complication is common in dialysis population and has a strong impact on patient survival [30]. Reduction in SFA intake for the benefit of polyunsaturated fatty acids (PUFA) consumption was shown to decrease the risk of sarcopenia [31]. It must be stressed, however, that in our analysis we have not found any associations between SFA and body mass index (BMI).

Substantial limitations of the present study need to be addressed. The major one is the small number of patients, additionally treated in only one dialysis unit. However, in our opinion even with these numbers the results are convincing. The association between SFA content/intake and mortality is evident, as shown in Kaplan–Meier analyses. However, as the study demonstrates, the patient outcome is probably due to other factors, such as co-morbidities, not to the detrimental impact of SFA themselves. Another potential limitation might be combining patients treated with different dialysis methods (PD and HD), as well as patients treated with lipid-lowering therapy. Patients treated with PD are characterized by different CV risk factors than HD patients. For instance, they have a tendency for higher cholesterol concentrations because of the dialysis-associated glucose load, while HD patients are subject to lower hemoglobin concentrations because of blood
losses during the dialysis procedure. Still, the CV mortality and the overall outcome are comparable with these two dialysis methods, as are the baseline characteristics of patients in our study who were stratified according to their treatment modality (Table S2). Similarly, there were no significant differences in patients stratified according the the use of lipid-lowering medications (Table S1). Furthermore, the FFQ-6, although validated for the national population, has not been verified in dialysis patients. Finally, the observational character of the study precludes analysis of causative relationships between SFA and outcomes and leaves us only with hypotheses.

5. Conclusions

In conclusion, in our cohort of patients undergoing dialysis a strong relationship between serum SFA content, as well as SFA intake and survival, has been demonstrated. This association turned out to be significantly dependent on the co-existing illnesses that themselves constitute strong risk factors for poor outcomes. Whether SFA contributes to these diseases or acts just as innocent by-standers, can be determined solely through interventional studies.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11175051/s1, Table S1: Baseline characteristics of the studied patients stratified according to the use of HMG-CoA reductase inhibitors (statins). Table S2: Baseline characteristics of the studied patients stratified according to their dialysis treatment.

Author Contributions: M.S.-W. and M.C. collected research material and analyzed clinical data; A.M., M.C. and T.S. designed the research; A.M. performed the laboratory analysis; all authors analyzed the data, contributed to writing the manuscript, and approved the final version. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by grant No 01-0513/08/122 of the strategic program “Excellence Initiative—Research University (IDUB)” run by the Ministry of Science and Higher Education of the Republic of Poland and by the Office for Science of the Medical University of Gdansk.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Ethics Committee of the Medical University of Gdansk (protocol no. NKEBN/614/2013-2014).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Data is contained within the article or supplementary material.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Zdrojewski, L.; Zdrojewski, T.; Rutkowski, M.; Bandosz, P.; Król, E.; Wyrzykowski, B.; Rutkowski, B. Prevalence of chronic kidney disease in a representative sample of the Polish population: Results of the NATPOL 2011 survey. Nephrol. Dial. Transplant. 2016, 31, 433–439. [CrossRef] [PubMed]
2. Hill, N.R.; Fatoba, S.T.; Oke, J.L.; Hirst, J.A.; O’Callaghan, C.A.; Lasserson, D.S.; Hobbs, F.R. Global prevalence of chronic kidney disease—A systematic review and meta-analysis. PLoS ONE 2016, 11, e0158765. [CrossRef] [PubMed]
3. Webster, A.C.; Nagler, E.V.; Morton, R.L.; Masson, P. Lancet Publishing Group. Chronic Kidney Disease. Lancet 2017, 389, 1238–1252. [PubMed]
4. Chmielewski, M.; Carrero, J.J.; Nordfors, L.; Lindholm, B.; Stenvinkel, P. Lipid disorders in chronic kidney disease: Reverse epidemiology and therapeutic approach. J. Nephrol. 2008, 21, 635–644. [PubMed]
5. Czumaj, A.; Śledziński, T.; Carrero, J.J.; Stepnowski, P.; Sikorska-Wisniewska, M.; Chmielewski, M.; Mika, A. Alterations of Fatty Acid Profile May Contribute to Dyslipidemia in Chronic Kidney Disease by Influencing Hepatocyte Metabolism. Int. J. Mol. Sci. 2019, 20, 2470. [CrossRef]
6. Kim, O.Y.; Lee, S.M.; An, W.S. Impact of blood or erythrocyte membrane fatty acids for disease risk prediction: Focusing on cardiovascular disease and chronic kidney disease. Nutrients 2018, 10, 1454. [CrossRef]
7. Siri-Tarino, P.W.; Sun, Q.; Hu, F.B.; Krauss, R.M. Saturated fatty acids and risk of coronary heart disease: Modulation by replacement nutrients. Curr. Atheroscler. Rep. 2010, 12, 384–390. [CrossRef]
8. Kris-Etherton, P.M.; Krauss, R.M. Public health guidelines should recommend reducing saturated fat consumption as much as possible: YES. Am. J. Clin. Nutr. 2020, 112, 13–18. [CrossRef]
9. Astrup, A.; Magkos, F.; Bier, D.M.; Brenna, J.T.; de Oliveira Otto, M.C.; Hill, J.O.; King, J.C.; Mente, A.; Ordovas, J.M.; Volek, J.S.; et al. Saturated Fats and Health: A Reassessment and Proposal for Food-Based Recommendations: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2020, 76, 844–857. [CrossRef]

10. Noels, H.; Lehrke, M.; Vanholder, R.; Jankowski, J. Lipoproteins and fatty acids in chronic kidney disease: Molecular and metabolic alterations. Nat. Rev. Nephrol. 2021, 17, 528–542. [CrossRef]

11. Friedman, A.N.; Yu, Z.; Denski, C.; Tamez, H.; Wenger, J.; Thadhani, R.; Li, Y.; Watkins, B. Fatty acids and other risk factors for sudden cardiac death in patients starting hemodialysis. Am. J. Nephrol. 2013, 38, 12–18. [CrossRef]

12. Folch, J.; Lees, M.; Sloane Stanley, G.H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 1957, 226, 497–509. [CrossRef]

13. Kowalkowska, J.; Slowinska, M.A.; Slowinski, D.; Długosz, A.; Niedzwiedzka, E.; Wadolowska, L. Comparison of a full food-frequency questionnaire with the three-day unweighed food records in young Polish adult women: Implications for dietary assessment. Nutrients 2013, 5, 2747. [CrossRef]

14. Unhapipatpong, C.; Shantavasinkul, P.; Kasemsup, V.; Siriyotha, S.; Warodomwichit, D.; Maneesuwannarat, S.; Vathesatogkit, P.; Sriroa, P.; Thakkinstian, A. Tropical oil consumption and cardiovascular disease: An umbrella review of systematic reviews and meta analyses. Nutrients 2021, 13, 1549. [CrossRef]

15. Scientific Advisory Committee on Nutrition (SACN). Saturated Fats and Health: SACN Report; Scientific Advisory Committee on Nutrition (SACN): London, UK, 2013.

16. World Health Organization. Draft guidelines on saturated fatty acid and trans-fatty acid intake for adults and children. Public Consult. 2018, 2018, 1–103.

17. Sacks, F.M.; Lichtenstein, A.H.; Wu, J.H.Y.; Appel, L.J.; Creager, M.A.; Kris-Etherton, P.M.; Miller, M.; Rimm, E.B.; Rudel, L.L.; Robinson, J.G.; et al. Dietary fats and cardiovascular health: A presidential advisory from the American Heart Association. Circulation 2017, 136, e1–e23. [CrossRef]

18. Mozaffarian, D.; Michaud, S.P.; Wallace, S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: A systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2010, 7, e1000252. [CrossRef]

19. Sikorska-Wisniewska, M.; Mika, A.; Śledziński, T.; Małgorzewicz, S.; Stepnowski, P.; Rutkowski, B.; Chmielewski, M. Disorders of serum omega-3 fatty acid composition in dialyzed patients, and their associations with fat mass. Ren Fail. 2017, 39, 406–412. [CrossRef]

20. Siri-Tarino, P.W.; Sun, Q.; Hu, F.B.; Krauss, R.M. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. Am. J. Clin. Nutr. 2010, 91, 535–546. [CrossRef]

21. Mente, A.; De Koning, L.; Shannon, H.S.; Anand, S.S. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch. Int. Med. 2009, 169, 659–669. [CrossRef]

22. Jakobsen, M.U.; O’Reilly, E.J.; Heitmann, B.L.; Pereira, M.A.; Bälter, K.; Fraser, G.E.; Goldbourt, U.; Hallmans, G.; Knekt, P.; Liu, S.; et al. Major types of dietary fat and risk of coronary heart disease: A pooled analysis of 11 cohort studies. Am. J. Clin. Nutr. 2009, 89, 1425–1432. [CrossRef] [PubMed]

23. McNennen, P.L. Relative effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on cardiac arrhythmias in rats. Am. J. Clin. Nutr. 1993, 57, 207–212. [CrossRef] [PubMed]

24. McNennen, P.L.; Bridle, T.M.; Abeyswardena, M.Y.; Charnock, J.S. Dietary lipid modulation of ventricular fibrillation threshold in the marmoset monkey. Am. Heart J. 1992, 123, 1555–1561. [CrossRef]

25. Forouhi, N.G.; Koulman, A.; Sharp, S.J.; Imamura, F.; Kröger, J.; Schulze, M.B.; Crowe, F.L.; Huerta, J.M.; Guevara, M.; Beulens, J.W.; et al. Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: The EPIC-InterAct case-cohort study. Lancet Diabetes Endocrinol. 2014, 2, 810–818. [CrossRef]

26. Lin, J.-S.; Dong, H.-L.; Chen, G.-D.; Chen, Z.-Y.; Dong, X.-W.; Zheng, J.-S.; Chen, Y.-M. Erythrocyte saturated fatty acids and incident type 2 diabetes in Chinese men and women: A prospective cohort study. Nutrients 2018, 10, 1393. [CrossRef] [PubMed]

27. Huang, L.; Lin, J.S.; Aris, I.M.; Yang, G.; Chen, W.Q.; Li, L.J. Circulating saturated fatty acids and incident type 2 diabetes: A systematic review and meta-analysis. Nutrients 2019, 11, 998. [CrossRef] [PubMed]

28. Stratford, S.; Hoehn, K.L.; Liu, E.; Summers, S.A. Regulation of insulin action by ceramide: Dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J. Biol. Chem. 2004, 279, 36608–36615. [CrossRef]

29. Chavez, J.A.; Knotts, T.A.; Wang, L.-P.; Li, G.; Dobrowsky, R.T.; Florant, G.L.; Summers, S.A. A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J. Biol. Chem. 2003, 278, 10297–10303. [CrossRef]

30. Carrero, J.J.; Chmielewski, M.; Axelson, J.; Snaedal, S.; Heimbürger, O.; Bárány, P.; Sultman, M.E.; Lindholm, B.; Stenvinkel, P.; Quezhi, A.R. Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients. Clin. Nutr. 2008, 27, 557–564. [CrossRef]

31. Montiel-Rojas, D.; Santoro, A.; Nilsson, A.; Franceschi, C.; Capri, M.; Bazzocchi, A.; Battista, G; De Groot, L.C.P.G.M.; Feskens, E.J.M.; Berendsen, A.A.M.; et al. Beneficial role of replacing dietary saturated fatty acids with polyunsaturated fatty acids in the prevention of sarcopenia: Findings from the nu-age cohort. Nutrients 2020, 12, 3079. [CrossRef]